View the latest news and SEC filings
Scroll to
Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
September 11, 2025 |
Additional proxy soliciting materials filed by non-management |
DFAN14A |
Proxy Filings |
|
|
September 10, 2025 |
Additional proxy soliciting materials – definitive |
DEFA14A |
Proxy Filings |
|
|
September 9, 2025 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
September 9, 2025 |
Additional proxy soliciting materials – definitive |
DEFA14A |
Proxy Filings |
|
|
September 3, 2025 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
September 3, 2025 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
September 3, 2025 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 18, 2025 |
Definitive proxy statement relating to merger or acquisition |
DEFM14A |
Mergers & Acquisitions |
|
|
August 14, 2025 |
SCHEDULE 13G/A – Description |
SCHEDULE 13G/A |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
